INNOVIVA, INC. Depreciation
INNOVIVA, INC. (INVA) reported Depreciation of $200.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2018-02-23
- INNOVIVA, INC. depreciation for fiscal 2017 was $200.00K, a 100.00% increase from fiscal 2016.
- INNOVIVA, INC. depreciation for fiscal 2016 was $100.00K, a 0.00% change from fiscal 2015.
- INNOVIVA, INC. depreciation for fiscal 2015 was $100.00K, a 90.91% decline from fiscal 2014.
- INNOVIVA, INC. depreciation for fiscal 2014 was $1.10M, a 59.26% decline from fiscal 2013.
| Period end | Depreciation 12 month |
|---|---|
| 2017-12-31 | $200.00K 10-K · filed 2018-02-23 |
| 2016-12-31 | $100.00K 10-K · filed 2018-02-23 |
| 2015-12-31 | $100.00K 10-K · filed 2018-02-23 |
| 2014-12-31 | $1.10M 10-K · filed 2017-02-28 |
| 2013-12-31 | $2.70M 10-K · filed 2016-02-24 |
| 2012-12-31 | $3.30M 10-K · filed 2015-02-27 |
| 2011-12-31 | $3.80M 10-K · filed 2014-03-03 |
| 2010-12-31 | $3.90M 10-K · filed 2013-02-26 |
| 2009-12-31 | $4.30M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |